X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the acquisition, Pyxis Oncology positions at forefront of Antibody-Drug Conjugate (ADC) development by adding PYX-107 (sotigalimab), a potential best-in-class Phase 2 CD40 agonist in clinical development for liposarcoma, melanoma, and other cancers.
Lead Product(s): Sotigalimab
Therapeutic Area: Oncology Product Name: PYX-107
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pyxis Oncology
Deal Size: $10.7 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 23, 2023
Details:
Through the acquisition, Pyxis Oncology positions at forefront of Antibody-Drug Conjugate (ADC) development by adding APX 005 (sotigalimab), a potential best-in-class Phase 2 CD40 agonist in clinical development for liposarcoma, melanoma, and other cancers.
Lead Product(s): Sotigalimab
Therapeutic Area: Oncology Product Name: APX 005
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pyxis Oncology
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 24, 2023
Details:
The gross proceeds will be used to finance and further support the company’s ongoing Phase 2 clinical study evaluating its CD40 antibody, APX005M (sotigalimab), in combination with doxorubicin in patients with liposarcoma.
Lead Product(s): Sotigalimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: APX005M
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Brookline Capital Markets
Deal Size: $2.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 24, 2023
Details:
Sotiga (sotigalimab) is a humanized monoclonal antibody that binds CD40 with high affinity and activates antigen presenting cells (dendritic cells, monocytes and B cells) leading to stimulation of cancer-specific T-cell responses leading tumor-specific immune activation.
Lead Product(s): Sotigalimab,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Sotiga
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
APX005M (sotigalimab) is a CD40 agonist that has been designed to reverse the systemic immune suppression that typically affects cancer patients, through the activation of several mechanisms of immune functionality.
Lead Product(s): Sotigalimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: APX005M
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
The combination of intratumoral sotigalimab and systemic pembrolizumab was well-tolerated and demonstrated an improved clinical response rate relative to the standard of care, pembrolizumab monotherapy.
Lead Product(s): Sotigalimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: Sotiga
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Sotiga (sotigalimab) in combination with neoadjuvant chemoradiation induced higher pathologic complete response rates, an important predictor of survival, in patients with both adenocarcinoma and squamous cell carcinoma.
Lead Product(s): Sotigalimab,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Sotiga
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
Sotigalimab (sotiga), Apexigen’s agonist antibody targeting CD40, in combination with neoadjuvant chemoradiation for patients with resectable esophageal and gastroesophageal junction (GEJ) cancers.
Lead Product(s): Sotigalimab
Therapeutic Area: Oncology Product Name: Sotiga
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
APX005M (Sotigalimab) is a potent CD40 agonist that has been designed to reverse the systemic immune suppression that typically affects cancer patients, through the activation of several mechanisms of immune functionality.
Lead Product(s): Sotigalimab,Nivolumab,Paclitaxel
Therapeutic Area: Oncology Product Name: APX005M
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Intratumoral CD40 agonist APX005M (sotigalimab) with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors in metastatic melanoma.
Lead Product(s): Sotigalimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: APX005M
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
In an ongoing Phase 2 clinical trial, sotigalimab is being evaluated in advanced soft tissue sarcoma in combination with doxorubicin, a chemotherapy that is currently considered standard-of-care treatment.
Lead Product(s): Sotigalimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: APX005M
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Details:
Apexigen is evaluating APX005M in a broad clinical program that includes more than 10 clinical trials in various indications and therapeutic combinations. APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response.
Lead Product(s): Sotigalimab,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: APX005M
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
Apexigen intends to use these proceeds to support the ongoing clinical development of its lead immunotherapeutic.
Lead Product(s): Sotigalimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Decheng Capital
Deal Size: $123.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
